A TRIAL OF LOBAPLATIN (D-19466) IN PLATINUM-RESISTANT OVARIAN-CANCER

Basit Öğe Kaydı
dc.contributor.authorKAVANAGH, JJ
dc.contributor.authorEDWARDS, CL
dc.contributor.authorFREEDMAN, RS
dc.contributor.authorFINNEGAN, MB
dc.contributor.authorBALAT, O
dc.contributor.authorTRESUKOSOL, D
dc.contributor.authorBURK, K
dc.date.accessioned2024-08-04T20:11:49Z
dc.date.available2024-08-04T20:11:49Z
dc.date.issued1995
dc.departmentİnönü Üniversitesien_US
dc.description.abstractLong-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy, A fundamental difficulty is the development of tumor resistance to platinum compounds, Analogs have been developed that demonstrate activity in platinum-resistant cell lines both in vitro and in vivo. Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resistant cell lines, Lobaplatin was given to 17 assessable patients with platinum-refractory ovarian cancer. The drug was initially administered at a dose of 50 mg/m(2) but was later reduced to 40 mg/m(2) because of excessive thrombocytopenia, Nine patients required red cell transfusions during therapy, Cycles were repeated every 21-35 days (median cycle length 28 days), No objective responses were observed, Lobaplatin has no activity in platinum-resistant epithelial ovarian cancer. (C) 1995 Academic Press, Inc.en_US
dc.identifier.doi10.1006/gyno.1995.1191
dc.identifier.endpage109en_US
dc.identifier.issn0090-8258
dc.identifier.issn1095-6859
dc.identifier.issue1en_US
dc.identifier.pmid7789874en_US
dc.identifier.scopus2-s2.0-0029075747en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage106en_US
dc.identifier.urihttps://doi.org/10.1006/gyno.1995.1191
dc.identifier.urihttps://hdl.handle.net/11616/93011
dc.identifier.volume58en_US
dc.identifier.wosWOS:A1995RG49700018en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Inc Elsevier Scienceen_US
dc.relation.ispartofGynecologic Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCarcinomaen_US
dc.titleA TRIAL OF LOBAPLATIN (D-19466) IN PLATINUM-RESISTANT OVARIAN-CANCERen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu